was removed by filtration through Celite, and solvent was removed in vacuo. Labile tritium was removed by codistillation with methanol (3 × 2 mL) under reduced pressure. Analysis of the crude product (287 mCi) by TLC [Whatman LK6F silica gel, CHCl$_3$/CH$_3$OH (90:10), developed 2 × 15 cm] indicated a purity of 52% (R_f = 0.33) with the remaining activity in higher R_f components. A 114 mCi portion of this material was purified by preparative TLC using the above system on four 5 × 20 cm plates (analytical grade). The product was recovered by extraction with methanol and purified again by the same procedure to remove a small amount of impurity at R_f = 0.4. A total of 41.6 mCi of pure [^{3}H]-**5** was obtained, with a specific activity of 16.2 Ci mmol^{-1} (spectrophotometric determination in 95% ethanol using ϵ_{254} = 1.11 × 10^4).

Radiochemical purity of this material was determined to be ≥98% by TLC and HPLC [HPLC system: Varian 5500 instrument, Whatman Partisil 5, 4.6 × 250 mm column, mobile phase 13% 80:20:05 CHCl$_3$/MeOH/Et$_3$N in CHCl$_3$, flow rate 1.0 mL min^{-1}, Varian UV-200 UV detector, Radiomatic HP30 Flo-One radiodetector. t_R for compound **5** = 11.5 min, t_R for compound **9** = 10.4 min].

Binding Methods. Mouse neuroblastoma–glioma cells (NG 108-15 cell line) were harvested and centrifuged at 900g at 4 °C for 10 min. The resulting pellet was resuspended in 10 mL of 20 mM Tris-HCl, 154 mM NaCl, pH 7.5 solution and homogenized with a Polytron (setting 9, 2 × 15 s). The suspension was spun as before. The final supernatant was diluted with Tris-HCl–NaCl buffer to yield 50 mg tissue/mL and stored for later use at –60 °C.

Cell suspension (150 μL) was incubated at 37 °C for 15 min with 0.1–10 nM of radioligand in 20 mM Tris-HCl, 154 mM NaCl, pH 7.5 solution in a final volume of 250 μL. Nonspecific binding was determined by 10 μM zacopride. Incubations were terminated by rapid filtration through 0.2% PEI-soaked borosilicate filtermats and washed with ice-cold Tris-HCl-NaCl buffer (3 × 5 mL). Filters were soaked overnight in 4 mL of Ecolume, and the retained radioactivity was determined with an LKB liquid-scintillation counter. Data were analyzed with the Lundon 1 software program.

Variation in the Aromatic Ring of Cromakalim: Antihypertensive Activity of Pyranopyridines and 6-Alkyl-2*H*-1-benzopyrans

Gordon Burrell,[†] Frederick Cassidy, John M. Evans,* Diane Lightowler,[‡] and Geoffrey Stemp

SmithKline Beecham Pharmaceuticals, Medicinal Research Centre, The Pinnacles, Harlow, Essex CM19 5AD, England. Received February 12, 1990

The synthesis and antihypertensive activity in the spontaneously hypertensive rat of two new series of analogues related to cromakalim (1) are described. In the first series, where the benzopyran nucleus has been replaced by a pyranopyridine nucleus, the position of the nitrogen atom has been found to be critical for activity, and the most potent compounds are the pyrano[3,2-c]pyridines. In the second series, where the powerful electron-withdrawing cyano group of compound 1 has been replaced by alkyl and phenyl groups, the order of antihypertensive potency is ethyl, isopropyl, *tert*-butyl > propyl, cyclopentyl > methyl > phenyl.

Since the discovery[1] that cromakalim (1) exerts its antihypertensive effect by a mechanism involving the enhanced outward flow of potassium ions through, and hyperpolarization of, the membranes of smooth muscle cells, several other compounds have been found to possess similar properties.

Thus, the established vasodilator pinacidil (2), together with minoxidil sulfate (3), diazoxide (4), and more recently RP49356 (5) (see Chart I) have all been reported[2] to be potassium-channel activators.

In previous papers we have described the structure–activity relationships pertaining to compound 1 and its cyclic amido[3] and acyclic amido[4] analogues, deduced from oral administration to spontaneously hypertensive rats (SHR). One of the conditions that was required for optimum activity was the presence of a powerful electron-withdrawing group such as nitro or cyano at position C(6) of the benzopyran ring. Mapping of two-dimensional electrostatic potentials of compound 1 and its analogues containing strong electron-withdrawing groups led us to synthesize pyrano[3,2-c]pyridine 7 (see Table I), as this ring system was shown to be electronically similar to the 6-cyanobenzopyran ring in these studies. The good blood pressure lowering activity of compound 7 confirmed the theoretical approach, and certain analogues have been

Chart I

cromakalim (1)

pinacidil (2)

minoxidil sulfate (3)

diazoxide (4)

RP49356 (5)

prepared (Table I) to establish structure–activity relationships in this first series of compounds.[5]

(1) Hamilton, T. C.; Weir, S. W.; Weston, A. H. *Br. J. Pharmacol.* **1986**, *88*, 103.

(2) Robertson, D. W.; Steinberg, M. I. *Annual Reports in Medicinal Chemistry*; Allen, R. C., Ed.; Academic Press: San Diego, 1989; Vol. 24, p 91.

(3) Ashwood, V. A.; Buckingham, R. E.; Cassidy, F.; Evans, J. M.; Faruk, E. A.; Hamilton, T. C.; Nash, D. J.; Stemp, G.; Willcocks, K. *J. Med. Chem.* **1986**, *29*, 2194.

(4) Ashwood, V. A.; Cassidy, F.; Coldwell, M. C.; Evans, J. M.; Hamilton, T. C.; Howlett, D. R.; Smith, D. M.; Stemp, G. *J. Med. Chem.*, in press.

†Present address: Glaxochem Ltd., Ulverston, Cumbria, England.
‡Present address: Merck, Sharp, and Dohme Research Laboratories Ltd., Neuroscience Research Centre, Terlings Park, Harlow, England.

Table I. *trans*-3,4-Dihydro-4-(2-oxopyrrolidin-1-yl)-2H-pyranopyridin-3-ols and Analogues

compd	R_1	N-posn	R_2 R_3	R_4	R_5	% yield	mp, °C	recryst solv[a]	formula	anal.[b]	dose, mg/kg po	% max fall in[c] bp ± SEM
1[d]	CN		-(CH₂)₃-	OH	H						0.1	13 ± 5
											0.3	39 ± 4
											1.0	47 ± 1
6	H	5	-(CH₂)₃-	OH	H	31	214–215	E-P	C₁₄H₁₈N₂O₃	C,H,N	10.0	15 ± 3
7		6	-(CH₂)₃-	OH	H	12	253	E	C₁₄H₁₈N₂O₃	C,H,N	1.0	39 ± 7
											3.0	41 ± 4
8	H	7	-(CH₂)₃-	OH	H	21	221–225	E-M	C₁₄H₁₈N₂O₃	H,N;C[e]	1.0	7 ± 3
											10.0	41 (2)
9	H	8	-(CH₂)₃-	OH	H	30	202–203	E-P	C₁₄H₁₈N₂O₃	C,H,N	10.0	5 ± 3
10		6	-(CH₂)₄-	OH	H	16	241–243	E	C₁₅H₂₀N₂O₃	C,H,N	0.1	24 ± 4
											0.3	55 ± 4
											1.0	56 ± 4
11	O	6	-(CH₂)₄-	OH	H	75	290–291	E-M	C₁₅H₂₀N₂O₄	C,H,N	0.3	39 ± 0
											1.0	68 ± 1
12		6	-(CH₂)₄-	bond		31	108–113	E-P	C₁₅H₁₈N₂O₂	C,H,N	1.0	14 ± 4
											3.0	37 ± 3
13		6	H Me	OH	H	32	208–210	E	C₁₂H₁₆N₂O₃	C,H,N	0.3	14 ± 2
											1.0	43 ± 5

ᵃ E = EtOAc, M = MeOH, P = pentane. ᵇ Analyses for the elements indicated were witin ±0.4% of the theoretical values. ᶜ Systolic blood pressure was measured indirectly at intervals from 1 to 6 h in groups of six SH rats per dose level. On occasion pulses were determined from only (n) SH rats. ᵈ See ref 6. ᵉ C: calcd, 64.11; found, 63.67.

Table II. *trans*-6-Alkyl-3,4-dihydro-4-(2-oxopyrrolidin-1-yl)-2H-1-benzopyran-3-ols and Analogues

| compd	R_1	R_2 R_3	% yield	mp, °C	recryst solv[a]	formula	anal.[b]	dose, mg/kg po	% max fall in[c] bp ± SEM
14	CF₃	-(CH₂)₃-	44	181–182	E	C₁₆H₁₈NO₃F₃	H,N;C[d]	0.1	17 ± 2
								0.3	26 ± 4
								1.0	43 ± 5
15[e]	H	-(CH₂)₃-						10.0	9 ± 4
16	Me	-(CH₂)₃-	35	187–188	E-P	C₁₆H₂₁NO₃	C,H,N	3.0	12 ± 6
								10.0	49 ± 7 (4)
17	Me	-(CH₂)₄-	15	162–164	E	C₁₇H₂₃NO₃	C,H,N	0.3	16 ± 5
								1.0	33 ± 2
								3.0	56 ± 2
18	Et	-(CH₂)₃-	49	154–163	E-PE	C₁₇N₂₃NO₃	C,H,N	0.3	11 ± 4
								1.0	54 ± 2
19	Me(CH₂)₂	-(CH₂)₃-	15	139–140	E	C₁₈H₂₅NO₃	C,H,N	1.0	17 ± 7
								3.0	42 ± 7 (5)
20	Me₂CH	-(CH₂)₃-	32	167–173	E	C₁₈H₂₅NO₃	C,H,N	0.3	17 ± 4
								1.0	36 ± 5
								3.0	60 (2)
21	Me₃C	-(CH₂)₃-	16	227–228	E-PE	C₁₉H₂₇NO₃	C,H,N	0.3	9 ± 5
								1.0	39 ± 9
								3.0	49 ± 6 (4)
22	c-C₅H₉	-(CH₂)₃-	27	179–184	E	C₂₀H₂₇NO₃	C,H,N	1.0	24 ± 2
								10.0	66 ± 2 (3)
23	Ph	-(CH₂)₃-	10	217–220	E-P	C₂₁H₂₃NO₃	C,H,N	3.0	14 ± 5
								10.0	20 ± 2 (4)
24	Me	H Me	21	188–190	E	C₁₄H₁₉NO₃·0.25H₂O	C,H,N	0.3	9 ± 4
								3.0	20 ± 6

ᵃ E = EtOAc, P = pentane, PE = 60–80 °C petroleum ether. ᵇ,ᶜ See footnotes b and c of Table I. ᵈ C: calcd, 58.36; found, 59.63. ᵉ See ref 3.

In accordance with the requirement for a strong electron-withdrawing group, 6-CF₃ compound 14 showed good

(5) Evans, J. M.; Cassidy, F.; Stemp, G. Partly presented at the 197th ACS National Meeting, Dallas, Texas, 1989, Symposium on Potassium Channels.

activity (Table II), while the unsubstituted compound 15 did not lower blood pressure at the top dose investigated (10 mg/kg).³ However, in stark contrast to these results, the 6-methyl compound 16 had surprisingly good activity at 10 mg/kg, producing a fall of approximately 50%. This result prompted an investigation of a series of 6-alkyl

Scheme I

analogues of compound **16** (see Table II).[5]

Chemistry

Synthesis of pyranopyridines **6–10** (see Table I) required as starting materials the appropriate 2,2-dimethyl-2*H*-pyranopyridines **25**, the syntheses of which have been reported recently.[6] Thus by the established route for compound **1**, compounds **6, 7, 9**, and **10** were prepared (Scheme I) via bromohydrin **26** and epoxide **27**. Compounds **6, 7**, and **9** were obtained by the action of pyrrolidone and compound **10** was obtained by the action of piperidone on the appropriate epoxide **27** in the presence of NaH base. The synthesis of compound **8** required changes in strategy as treatment of pyrano[2,3-*c*]pyridine **25** (7-N) with moist NBS failed to give a bromohydrin. However, conversion of pyrano[2,3-*c*]pyridine **25** to its *N*-oxide with *m*-CPBA followed by treatment with moist NBS gave bromohydrin **26** (7-N$^+$-O$^-$). Conversion of bromohydrin **26** (7-N$^+$-O$^-$) to epoxide **27** (7-N$^+$-O$^-$) was followed by treatment with ammonia and amino alcohol **28** acylated with chlorobutyryl chloride to give (chlorobutyryl)amino compound **29**, as epoxide **27** (7-N$^+$-O$^-$) failed to react with pyrrolidone under the usual conditions described for the preparation of compounds **6, 7**, and **9**. Ring closure under basic conditions yielded pyrrolidone **30**. Deoxygenation of **30** with hexachlorodisilane[7] provided the required compound **8**. Treatment of compound **10** with *m*-CPBA gave the *N*-oxide **11**, and dehydration of **10** with NaH gave the dihydro compound **12** (Scheme II). Finally, the pyrano[3,2-*c*]-pyridine epoxide **27** (6-N) was treated with ammonia, and amino alcohol **31** was acylated with acetyl chloride to give compound **13** (Scheme II).

Scheme II

The synthesis of the 6-CF$_3$ compound **14**, the 6-alkyl compounds **16–22**, and the 6-phenyl compound **23** also followed the established synthetic route (see Scheme III) devised for compound **1**. Thus the appropriate phenols were alkylated with 3-chloro-3-methylbut-1-yne under phase-transfer catalytic conditions to furnish 3-methyl-3-(4-substituted-phenoxy)-but-1-ynes **32**. These were thermally cyclized in boiling *o*-dichlorobenzene to give 6-substituted chromenes **33** as oils, which were characterized by NMR spectroscopy before being converted directly into bromohydrins **34** by treatment with aqueous NBS. Action of base yielded epoxides **35** which were treated with the appropriate cyclic amide and 1 equiv of NaH to give compounds **14** and **16–23** (Table II). The 6-methyl epoxide **35** (R = Me)[8] was converted to amino alcohol **36** and reacted with acetyl chloride to give compound **24**.

Results and Discussion

Compounds were evaluated for oral antihypertensive activity in the SHR. Systolic blood pressure, recorded from the tail, was determined before dosing and at various time intervals during the ensuing 6 h. Maximum falls in blood pressure obtained for all the compounds (Tables I and II) occurred at 1–4 h postdose with some recovery to the predose level of blood pressure being observed at 6 h.

In the four isomeric pyranopyridine analogues **6–9**, structure–activity relationships are in line with previous results obtained[3] when variation of the position of substituents in the aromatic ring was studied and in agreement with the predictions from the modeling of two-dimensional electrostatic potentials. Thus the most potent compound (Table I) is pyrano[3,2-*c*]pyridine compound **7**, while the pyrano[2,3-*c*]pyridine compound **8** only possessed reasonable activity at the highest dose. The pyrano[3,2-*b*]- and -[2,3-*b*]pyridines compounds **6** and **9**, respectively, showed little activity at the highest dose employed. In the potent pyrano[3,2-*c*]pyridine series the homologous piperidone compound **10** showed enhanced activity over pyrrolidone **7**, a differential in activity first observed[3] for the piperidone analogue of compound **1**.

Preparation of the *N*-oxide of compound **10** resulted in an analogue, **11**, of similar potency, but the unsaturated variant **12** of compound **10** was found to be less active, thus illustrating again the variability in comparative activities

(6) Evans, J. M.; Stemp, G. *Synth. Commun.* **1988**, *18*, 1111.

(7) Naumann, K.; Zon, G.; Mislow, K. *J. Am. Chem. Soc.* **1969**, *91*, 2788.

(8) Evans, J. M.; Fake, C. S.; Hamilton, T. C.; Poyser, R. H.; Watts, E. A. *J. Med. Chem.* **1983**, *26*, 1582.

Scheme III

of 3-hydroxy compounds and dehydro compounds that we have reported previously.[3]

In accord with the earlier work, compound 14 (Table II) which contains the strong electron-withdrawing CF_3 group at C(6) showed good activity, being approximately equiactive with compound 1. Unsubstituted compound 15 was inactive at the dose tested, but 6-methyl compound 16, which is similar in shape but not in electronic effect to 6-CF_3 compound 14, had surprisingly good activity at 10 mg/kg. The possibility arises that the activity of compound 16 might be ascribed to the shape and/or lipophilicity of the C(6) substituent, and that the enhanced activity of compound 14 may be due to the additional electron-withdrawing properties of the CF_3 substituent when compared with a methyl substituent. Again piperidone compound 17 showed a greater potency than pyrrolidone compound 16, as was noted in the pyrano[3,2-c]pyridine series above.

Extension of the methyl group to ethyl as in compound 18 substantially enhanced the activity, but the n-propyl compound 19 was only about $^1/_3$ as potent as 6-ethyl compound 18. However, introduction of branched alkyl groups gave isopropyl (20) and *tert*-butyl (21) compounds of similar potency to the ethyl compound 18, while cyclopentyl analogue 22 was at least 3-fold less active than compound 18. Replacement of the alkyl group by a phenyl ring (compound 23) reduced activity to modest levels.

Representative acyclic amido analogues, 4-acetylamino compounds 13 (Table I) and 24 (Table II), have been prepared in the pyrano[3,2-c]pyridine and the 6-alkyl series, respectively. These compounds compare very favorably in potency with the equivalent pyrrolidones 7 and 16, respectively. Such equivalence has been reported previously[4] for the 4-(acetylamino) analogue of compound 1.

Experimental Section

Melting points were determined with a Büchi capillary melting point apparatus and are uncorrected. NMR spectra were recorded on a Varian EM 360A at 60 MHz, a Varian CFT-20 at 80 MHz, or a JEOL GX 270, and mass spectra were recorded on a VG 70-70 or 70 ZAB or a JEOL DX 303 at 70 eV, respectively, and were in agreement with the structures cited. HF_{254} silica gel plates (2 mm) were used for Chromatotron chromatography (radial chromatography). Petroleum ether refers to that fraction boiling between 60 and 80 °C. Two dimensional electrostatic potential maps were generated with a modified VSS procedure[9] from partial charges calculated by the semiempirical CNDO method.[10]

3-Methyl-3-(4-substituted-phenoxy)but-1-ynes (32). The appropriate phenol (0.06 mol) and NaOH (0.1 mol) were added to a stirred mixture of H_2O (60 mL) and CH_2Cl_2 (60 mL), followed by benzyltrimethylammonium hydroxide (40% in MeOH, 0.06 mol) and 3-chloro-3-methyl-but-1-yne (0.1 mol). The mixture was

(9) Giessner-Prettre, C. *QCPE* **1974**, No. 249.
(10) Dobosh, P. A. *QCPE* **1968**, No. 141.

stirred at room temperature for 4–11 days, and the layers were separated. The aqueous layer was extracted with $CHCl_3$, and the combined organic layer was concentrated in vacuo and taken up in Et_2O. The solution was washed with H_2O, 10% NaOH, and brine and dried over anhydrous $MgSO_4$. Filtration and evaporation gave compounds 32 in yields of 19–50%.

2,2-Dimethyl-6-substituted-2H-1-benzopyrans (33). Phenoxybutynes 32 (0.05 mol) were heated in o-dichlorobenzene (2 mL/g of 32) under N_2 for 2–12 h. Solvent was removed under vacuum, and crude 33 was used directly or, more usually, purified by chromatography on silica gel with EtOAc as eluant in yields of 20–90%. Compound 33, R = $C(Me)_3$: NMR ($CDCl_3$) δ 1.27 (s, $C(Me)_3$), 1.40 (s, $C(Me)_2$), 5.50 (d, J = 9 Hz, H-3), 6.25 (d, J = 9 Hz, H-4), 6.60 (d, J = 8 Hz, H-8), 7.10 (m, H-7 and H-5).

***trans*-3-Bromo-3,4-dihydro-2,2-dimethyl-6-substituted-2H-1-benzopyran-4-ols (34).** To a solution of the appropriate 2,2-dimethylbenzopyran 33 (10 mmol) in DMSO (35 mL) and H_2O (20 mL) was added NBS (20 mmol) and the mixture was stirred for 1 h. The solution was diluted with H_2O and extracted with EtOAc. The organic layer was washed with H_2O and brine and dried over $MgSO_4$. Filtration and evaporation gave bromohydrins 34, usually as oils (70–90%) which were characterized by NMR and high-resolution MS before conversion to epoxides 35. Compound 34 (R = Me_2CH): NMR ($CDCl_3$) δ 1.20 (d, J = 7 Hz, Me_2CH), 1.37 (s, $C(Me)_2$), 1.55 (s, $C(Me)_2$), 2.80 (sept, J = 7 Hz, Me_2CH), 4.03 (d, J = 9 Hz, H-3), 4.80 (m, H-4), 6.55 (d, J = 8 Hz, H-8), 6.80–7.20 (m, H-5, H-7); mass spectrum, observed M$^+$ at m/z 298.0563, 300.0553; $C_{14}H_{19}O_2Br$ requires 298.0568, 300.0548. Compound 34 (R = Ph): 69%; mp 135–139 °C (EtOAc–petroleum ether). Anal. ($C_{17}H_{17}O_2Br$) C, H, Br. Compound 34 (R = c-C_5H_9): 92%; mp 121–122 °C (EtOAc–petroleum ether). Anal. ($C_{16}H_{21}O_2Br$) C, H. Compound 34 (R = ^tBu): 18%; mp 122–123 °C (EtOAc–petroleum ether). Anal. ($C_{15}H_{21}O_2Br0.5H_2O$) C, H.

3,4-Epoxy-3,4-dihydro-2,2-dimethyl-6-substituted-2H-1-benzopyrans (35). Bromohydrins 34 (5 mmol) were stirred with KOH pellets (5 mmol) in Et_2O (250 mL) at room temperature for 1–4 days. Filtration and evaporation gave epoxides 35, which were used directly. Compound 35 (R = Me_2CH); NMR ($CDCl_3$) δ 1.20 (d, J = 7 Hz, Me_2CH) overlapping 1.20 (s, $C(Me)_2$), 1.50 (s, $C(Me)_2$), 2.80 (sept, J = 7 Hz, Me_2CH), 3.40 (d, J = 4 Hz, H-3), 3.80 (d, J = 4 Hz, H-4), 6.60 (d, J = 8 Hz, H-8), 6.80–7.30 (m, H-5, H-7).

***trans*-4-Amido-3,4-dihydro-2,2-dimethyl-6-substituted-2H-1-benzopyrans (14, 16–23).** The requisite cyclic amide (5 mmol) was treated with 80% NaH (5 mmol) and the appropriate epoxide (5 mmol) in Me_2SO (40 mL) with stirring under N_2 for 2–6 h. The reaction mixture was diluted with H_2O and extracted with EtOAc. The organic layer was washed with H_2O and brine and dried over anhydrous $MgSO_4$. Filtration and evaporation gave the title compounds as crude solids which were purified by chromatography and recrystallization (see Table II). Compound 14: NMR ($CDCl_3$) δ 1.30 (s, $C(Me)_2$), 1.50 (s, $C(Me)_2$), 2.15 (m, NCH_2CH_2), 2.50 (m, $NCOCH_2$), 3.20 (m, NCH_2), 3.75 (d, J = 10 Hz, H-3), 4.60 (br s, OH), 5.25 (d, J = 10 Hz, H-4), 6.80 (d, J = 8 Hz, H-8), 7.10 (d, J = 2 Hz, H-5), 7.30 (dd, J = 8, 2 Hz, H-7).

2,2-Dimethyl-2H-pyrano[2,3-c]pyridine N-Oxide (25 N-Oxide). To a stirred solution of 2,2-dimethyl-2H-pyrano-[2,3-c]pyridine[6] (25, 8.64 g, 54 mmol) in $CHCl_3$ was added m-CPBA (9.15 g, 53 mmol) portionwise during 15 min. The solution was then boiled for 1 h, cooled, and evaporated, and the residue was

chromatographed on silica gel (500 g). Elution with 5% MeOH–CHCl₃ gave **25** (*N*-oxide) (5.96 g, 61%) as a colorless gum: NMR (CDCl₃) δ 1.45 (s, C(Me)₂), 5.73 (d, *J* = 10 Hz, H-3), 6.27 (d, *J* = 10 Hz, H-4), 6.87 (d, *J* = 6 Hz, H-5), 7.75 (m, H-6, H-8).

***trans*-3-Bromo-3,4-dihydro-2,2-dimethyl-2*H*-pyrano-pyridin-3-ols (26).** 2,2-Dimethyl-2*H*-pyranopyridines **25** were treated in a manner identical with that for 2*H*-1-benzopyrans **33** with aqueous NBS. The crude solids were purified by recrystallization, after optional chromatography. Compound **26** (3,2-*b*): 59%; mp 133–135 °C (radial chromatography eluted with 30% ethyl acetate–petroleum ether). Anal. (C₁₀H₁₂NO₂Br) C, H, N. Compound **26** (3,2-*c*): 34%; mp 140–141 °C (EtOAc–pentane). Anal. (C₁₀H₁₂NO₂Br) C, H, N. Compound **26** (2,3-*c* *N*-oxide): 68%; mp 185–187 °C (EtOAc–MeOH). Anal. (C₁₀H₁₂NO₃Br) C, H, N. Compound **26** (2,3-*b*): 89%; mp 163–165 °C (EtOAc). Anal. (C₁₀H₁₂NO₂Br) C, H, N.

3,4-Epoxy-3,4-dihydro-2,2-dimethyl-2*H*-pyranopyridines (27). Bromohydrins **26** were treated as bromohydrins **34** with KOH/Et₂O to give epoxides **27**, which were used directly. Bromohydrin **26** (2,3-*c* *N*-oxide, 1.56 g, 5.5 mmol) and powdered KOH pellets (2.0 g, 36 mmol) were stirred and heated under reflux in THF (150 mL) for 4 h. The solution was cooled, filtered, and evaporated to give epoxide **27** (2,3-*c* *N*-oxide, 1.01 g, 91%) as a glass: NMR (CDCl₃) δ 1.31 (s, C(Me)₂), 1.58 (s, C(Me)₂), 3.51 (d, *J* = 4 Hz, H-3), 3.88 (d, *J* = 4 Hz, H-4), 7.20 (d, *J* = 7 Hz, H-8), 7.75 (m, H-5, H-7), which was used directly in the preparation of compound **30**.

***trans*-3,4-Dihydro-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-2*H*-pyrano[3,2-*c*]pyridin-3-ol (7).** [3,2-*c*]Epoxide **27** (0.43 g, 2.4 mmol) was added to a stirred solution of 2-pyrrolidone (0.22 mL, 2.9 mmol) in dry DMSO (10 mL) containing NaH (80 mg of 80% dispersion in oil, 2.7 mmol) under N₂ at room temperature. The reaction mixture was stirred for an additional 24 h. Water (100 mL) was added cautiously and the aqueous layer was extracted into EtOAc. The organic layer was washed with H₂O (at pH 7) and brine and then dried over anhydrous MgSO₄. Filtration and evaporation, followed by radial chromatography (silica gel, gradient elution CHCl₃ to 20% MeOH–CHCl₃) and recrystallization, gave compound **3** (74 mg). Similarly prepared were compounds **6**, **9**, and **10** (using 2-piperidinone). See Table I.

***trans*-3,4-Dihydro-2,2-dimethyl-4-(2-oxopyrrolidinyl)-2*H*-pyrano[2,3-*c*]pyridin-3-ol *N*-Oxide (30).** Epoxide **27** (2,3-*c* *N*-oxide, 1.01 g, 5.2 mmol) was dissolved in dry ethanolic ammonia (30 mL) and maintained at room temperature for 7 days. Evaporation and trituration with EtOAc gave amino alcohol **28** (0.62 g, 56%) as a pale yellow solid. A sample recrystallized from EtOAc–MeOH had mp 206–208 °C. Anal. (C₁₀H₁₄N₂O₃) H; C, N: calcd C, 57.13, N, 13.33; found C, 56.69, N, 12.88.

To an ultrasonicated, stirred solution of amino alcohol **28** (1.54 g, 5.0 mmol) in CH₂Cl₂ (600 mL) and Et₃N (0.64 mL, 4.6 mmol) was added chlorobutyryl chloride (0.91 mL, 8.34 mmol). The ultrasonication and stirring were continued for 1 h. The solution was evaporated and the residue was chromatographed on silica gel (200 g) and eluted with a gradient of CHCl₃ to 10% MeOH–CHCl₃ to give compound **29** (1.0 g, 43%). To the (chlorobutyryl)amino compound **29** (487 mg, 1.55 mmol) dissolved in dry DMSO (10 mL) and dry THF (10 mL) was added 80 NaH (50 mg, 1.7 mmol), and the mixture was stirred for 16 h at room temperature. Water was added cautiously, and the resulting solution was extracted with CHCl₃. The organic layer was dried over anhydrous MgSO₄, filtered, and evaporated to give a solid which was recrystallized from EtOAc–MeOH to give compound **30** (135 mg, 31%): mp 268–271 °C. Anal. (C₁₄H₁₈N₂O₄) H, N; C: calcd, 60.42; found, 59.85.

***trans*-3,4-Dihydro-2,2-dimethyl-4-(2-oxopyrrolidinyl)-2*H*-pyrano[2,3-*c*]pyridin-3-ol (8).** To a stirred solution of compound **30** (0.24 g, 0.9 mmol) in CH₂Cl₂ (200 mL) was added Si₂Cl₆[7] (0.4 mL, 2.3 mmol) in CH₂Cl₂ (20 mL) dropwise under N₂. The mixture was stirred for 1 h before addition of a 10% aqueous NaOH solution (0.5 mL). The mixture was stirred for 10 min and evaporated to dryness. Extraction with CHCl₃ and with MeOH and evaporation of the mixture gave a gum which was purified with radial chromatography (gradient elution CHCl₃ to 10% MeOH–CHCl₃) to give title compound **8** (0.11 g) (see Table I).

***trans*-3,4-Dihydro-2,2-dimethyl-4-(2-oxopiperidinyl)-2*H*-pyrano[3,2-*c*]pyridin-3-ol *N*-Oxide (11).** A solution of compound **10** (0.1 g, 0.36 mmol) and *m*-CPBA (125 mg, 0.72 mmol) in CHCl₃ was heated under reflux for 1.5 h. The reaction mixture was cooled and evaporated and the residue was radially chromatographed with CHCl₃ to 10% MeOH–CHCl₃ in a gradient elution to give a gum which was recrystallized to give compound **11** (70 mg) (see Table I).

2,2-Dimethyl-4-(2-oxopiperidinyl)-2*H*-pyrano[3,2-*c*]pyridine (12). Compound **10** (0.4 g, 1.5 mmol) and NaH (88 mg of 80% dispersion in oil, 2.9 mmol) were boiled in dry xylene (35 mL) under N₂ for 2.5 h. The reaction mixture was cooled, and H₂O was added cautiously and the solution was evaporated to give a gum which was radially chromatographed with CHCl₃ to 25% MeOH–CHCl₃ in a gradient elution to give a solid which was recrystallized to give compound **12** (86 mg) (see Table I).

***trans*-4-(Acetylamino)-3,4-dihydro-2,2,6-trimethyl-2*H*-1-benzopyran-3-ol (24).** Epoxide **35** (R = Me, 7.0 g, 0.037 mol) was dissolved in 0.88 M NH₄OH solution (90 mL, 2.3 mmol) and EtOH (160 mL) and stirred at room temperature for 5 days. Evaporation gave crude amino alcohol **36** (7.0 g, 92%). To this amino alcohol (**36**; 1.0 g, 4.8 mmol) and Et₃N (0.67 mL, 4.8 mmol) dissolved in CH₂Cl₂ (60 mL) was added acetyl chloride (0.34 mL, 4.8 mmol) dropwise with stirring at room temperature. The reaction mixture was stirred for 3 h and then washed with H₂O and brine and dried over anhydrous MgSO₄. The solution was filtered and evaporated and the residue was radially chromatographed with a 30% pentane–EtOAc to EtOAc gradient elution, and the crude product was recrystallized to give compound **24** (0.25 g) (see Table II).

In a similar manner, ***trans*-4-(acetylamino)-3,4-dihydro-2,2-dimethyl-2*H*-pyrano[3,2-*c*]pyridin-3-ol (13)** was prepared from amino alcohol **31** (see Table I).

Pharmacological Testing. Hypertensive Rats. All of the test compounds, and the standard drug, were evaluated for antihypertensive activity in conscious, spontaneously hypertensive rats (14–24 weeks old), derived from the Japanese (Okamoto) strain. Animals with systolic blood pressure >180 mmHg (1 mmHg = 133 Pa) were considered to be hypertensive.

Systolic blood pressure was recorded by the tail-cuff method by using a W+W blood pressure recorder, Model no. 8005; each determination was the mean of at least six recordings. Blood pressure measurements were made prior to the oral administration of test compound and at intervals for up to 6 h postdose.

All compounds were administered (via an oral dosing needle placed in the esophagus) as a solution or suspension in 1% w/v methylcellulose solution.

With the use of the above procedure, vehicle alone typically has little or no effect on blood pressure apart from a slight reduction (by 5–10%) at 6 h postdose.